Clinical significance of serum S100A10 in lung cancer

Abstract

Objective To investigate the clinical significance of serum S100 calcium-binding protein A10 (S100A10) levels in lung cancer. Methods This prospective study enrolled patients with lung cancer, patients with benign lung nodules and healthy control subjects. Serum S100A10 levels and three biomarkers were measured and compared between the groups. Associations between serum S100A10 and clinical characteristics in patients with lung cancer were investigated. The diagnostic efficacy of serum S100A10 and carcinoembryonic antigen for lung cancer was calculated. Results The study enrolled 82 patients with lung cancer, 21 with benign lung nodules and 50 healthy controls. Serum S100A10 levels were significantly higher in patients with lung cancer compared with patients with benign lung nodules and healthy control subjects. Serum S100A10 levels of patients with advanced lung cancer were significantly higher than those with early stage disease. Patients with lymph node metastases had significantly higher serum S100A10 levels than patients without lymph node metastases. The cut-off serum S100A10 value for lung cancer detection was 1.34 ng/ml, which had a sensitivity of 48.2%, a specificity of 76.2% and an area under the curve of 0.63. Conclusion Serum S100A10 was significantly correlated with disease stage and lymph node metastasis. It has the potential to be a tumour biomarker for lung cancer.

S100A10 Promotes Pancreatic Ductal Adenocarcinoma Cells Proliferation, Migration and Adhesion through JNK/LAMB3-LAMC2 Axis

“…In lung squamous cell carcinoma, the expression of S100A10 in tumor tissue was positively correlated with tumor size, TMN stage, and lymphatic metastasis [8], while elevated S100A10 in lung adenocarcinoma indicated poorer tumor differentiation, higher TMN stage, more frequent intratumoral vascular invasion and a poorer prognosis [17]. What is more, the serum S100A10 levels in lung cancer were not only significantly higher than that in patients with benign lung nodules and healthy cancer-free controls but also positively associated with TNM stage and lymphatic metastasis [18], indicating that S100A10 is not only a prognostic marker but also a potential diagnostic maker for lung cancer. Similarly, Yi Tan et al reported that S100A10 might serve as a potential biomarker for early detection and a potential therapeutic target for gallbladder cancer [9].…”

S100A10 Overexpression Correlates with Adverse Prognosis, Tumor Microenvironment, and Aggressive Behavior In Vitro and In Vivo of Cervical Cancer

“…This, in turn, can cause matrix metalloproteinase activation, extracellular matrix degradation, and the consequent growth and invasivity of tumors [8]. Aberrant S100A10 upregulation has been reported in lung, gastric, ovarian, and breast cancers wherein it is associated with poorer prognostic outcomes [9][10][11][12]. To date, there have been no detailed analyses of S100A10 expression in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and further work is vital to clarify its biological activity in this deadly oncogenic context.…”